公司資料
Cerevel 股價、新聞與催化劑
- 股票代碼:
- CERE
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股價為何變動
Current closing-price context is not available for CERE.
公司概覽
業務概覽
Cerevel Therapeutics was a neuroscience biotech focused on receptor pharmacology and CNS drug development before being acquired by AbbVie.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ prior to acquisition, it sat in CNS biotechnology.
商業模式特徵
The story was built around clinical-stage psychiatry and neurology programs, with valuation tied to pipeline data and strategic interest.
生技產業定位
Cerevel was a high-quality neuroscience catalyst name and now belongs to biotech M&A history.
未來催化劑
- Cerevel’s near-term catalyst is mostly transaction resolution and any final closeout / integration-related milestone tied to the company’s acquired pipeline assets. The next update will help show whether the company is moving from promise to a more de-risked stage of execution. Investors will care less about the label than about whether the platform can keep producing credible next steps.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。